NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
15 Mar 2012

TiGenix Reports Full Year 2011 Financial Results.

Leuven (BELGIUM) – March 15, 2012 –TiGenix NV (NYSE Euronext: TIG) today gave a business update and announced financial results for the full year 2011.
13 Mar 2012

AM-Pharma Announces Appointment of Industry Expert Guido Magni as Board Member.

Bunnik, The Netherlands, 16 March 2012. AM‐Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and inflammatory bowel diseases, has appointed Dr Guido Magni as a member of its Supervisory Board.
16 Feb 2012

TiGenix announces changes in management responsibilities.

Leuven (BELGIUM) – February 16, 2012 – TiGenix (NYSE Euronext: TIG) announced today changes to executive responsibilities within the Company.
01 Feb 2012

TiGenix rheumatoid arthritis Phase IIa study opens third and last cohort.

Leuven (BELGIUM), Madrid (SPAIN) – February 1, 2012 – TiGenix (NYSE Euronext: TIG) announced today that upon review of the safety data of the first three patients of the second cohort of the company’s Phase IIa clinical trial in rheumatoid arthritis (Cx611) it has received the go-ahead from the independent Safety Monitoring Board to recruit and dose the remaining 20 patients of this cohort and to open the third and final cohort.
12 Jan 2012

AM-Pharma Announces Appointment of Russell Greig as Chairman.

Bunnik, The Netherlands, 4 January 2012. AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and Inflammatory bowel diseases, today announced the appointment of Dr Russell Greig as Chairman of the Supervisory Board.
12 Jan 2012

Endosense launches TactiCath 75 force-sensing catheter, announces new results of EFFICAS clinical study.

GENEVA – January 12, 2011 – Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced the European launch of the TactiCath 75 force-sensing ablation catheter as well as results of the EFFICAS clinical study of contact force-sensing in catheter ablation procedures.
09 Jan 2012

TiGenix Reports Positive Results of ChondroCelect. Compassionate Use Program.

Leuven (BELGIUM) – January 9, 2011 – TiGenix (NYSE Euronext: TIG), a leading biopharmaceutical company that commercializes and develops cell therapies, today announced data from a ChondroCelect® compassionate use program (CUP), involving 43 orthopedic centers in 7 European countries, treating 370 patients with ChondroCelect over the span of four years.
01 Dec 2011

Ysios Capital Partners and “la Caixa” lead MedLumics €3.5million/$4.7million Series A Financing.

MADRID - December 1, 2011 – MedLumics, a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology, has announced the closing of a 3.5 million Euro/4.7 million USD Series A financing.
01 Dec 2011

Ysios Capital Partners and “la Caixa” lead MedLumics €3.5million/$4.7million Series A Financing.

MADRID - December 1, 2011 – MedLumics, a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology, has announced the closing of a 3.5 million Euro/4.7 million USD Series A financing.
Ysios Capital Partners leads €29.2million Series D Financing of AM-Pharma<
13 Sep 2011

Ysios Capital Partners leads €29.2million Series D Financing of AM-Pharma

The oversubscribed series D round was led by Ysios Capital Partners, co-led by Kurma Life Science Partners.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.